Mast-Cell Stabilization to Decrease Neurofibroma Growth: Preliminary Experience With Ketotifen

doi:10.1001/archderm.1987.01660320053011

You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.

Vol. 123 No. 8, August 1987

Online Only
	•	Online First Table of Contents

STUDIES

•	Online Features

This Article
•	References
•	Full text PDF
•	Reply to article
•	Send to a friend
•	Save in My Folder
•	Save to citation manager
•	Permissions

Citing Articles
•	Citation map
•	Citing articles on HighWire
•	Citing articles on Web of Science (69)
•	Contact me when this article is cited

Related Content
•	Similar articles in this journal

Social Bookmarking
	What's this?

Mast-Cell Stabilization to Decrease Neurofibroma Growth

Preliminary Experience With Ketotifen

Vincent M. Riccardi, MD

Arch Dermatol. 1987;123(8):1011-1016.

Abstract

• Based on (1) the large numbers of mast cells presentin neurofibromas, (2) the possibility that these mast cellscontribute directly to neurofibroma growth, and (3) the abilityof ketotifen therapy to stabilize (ie, block) mast-cell secretion,treatment with ketotifen was started in a patient with severeneurofibromatosis (NF) in August 1983. Subsequently, ten additionalpatients with one or more symptomatic neurofibromas were treatedwith comparable doses of ketotifen, 2 to 4 mg/d, orally administeredfor 30 to 43 months. This represents a total of 389 patient-monthsor 32.4 patient-years. All of these patients showed an unequivocaldecrease in neurofibroma-associated pruritus and/or pain andtenderness; a consistent, but less-uniform, decrease in therate of neurofibroma growth; and an unexpected improvement inoverall sense of well-being, productivity, and general performance.It appears likely that mast-cell secretions do contribute tothe growth and associated symptoms of neurofibromas, and thatmast-cell blockers, such as ketotifen therapy, can retard thisgrowth.

(Arch Dermatol 1987;123:1011-1016)

Author Affiliations

From the Neurofibromatosis Program, Baylor College of Medicine, Houston.

Footnotes

Accepted for publication March 11, 1987.

Reprint requests to Neurofibromatosis Program, Baylor Collegeof Medicine, 1 Baylor Plaza, Houston, TX 77030 (Dr Riccardi).

Add to CiteULike CiteULike Add to Connotea Connotea Add to Delicious Delicious Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Different Patterns of Mast Cells Distinguish Diffuse from Encapsulated Neurofibromas in Patients with Neurofibromatosis 1
Tucker et al.
J Histochem Cytochem 2011;59:584-590.
ABSTRACT | FULL TEXT

Neurofibromatosis Type 1 Revisited
Williams et al.
Pediatrics 2009;123:124-133.
ABSTRACT | FULL TEXT

Review Article : Neurofibromas in Children With Neurofibromatosis 1
Rosser and Packer
J Child Neurol 2002;17:585-591.
ABSTRACT

Review ArticLe : Therapy for Plexiform Neurofibromas in Children With Neurofibromatosis 1: An Overview
Packer and Rosser
J Child Neurol 2002;17:638-641.
ABSTRACT

Plexiform neurofibromas in NF1: Toward biologic-based therapy
Packer et al.
Neurology 2002;58:1461-1470.
ABSTRACT | FULL TEXT

Of Mass and Men: Neurofibromas and Histogenesis
Riccardi
Arch Dermatol 2000;136:1257-1258.
FULL TEXT

Protection From Apoptosis by Steel Factor But Not Interleukin-3 Is Reversed Through Blockade of Calcium Influx
Gommerman and Berger
Blood 1998;91:1891-1900.
ABSTRACT | FULL TEXT

A Controlled Multiphase Trial of Ketotifen to Minimize Neurofibroma-Associated Pain and Itching
Riccardi
Arch Dermatol 1993;129:577-581.
ABSTRACT

Abnormal Nevoblast Migration Mimicking Neurofibromatosis
Lycka et al.
Arch Dermatol 1991;127:1702-1704.
ABSTRACT

Neurofibromatosis 1 (Recklinghausen Disease) and Neurofibromatosis 2 (Bilateral Acoustic Neurofibromatosis) An Update
Mulvihill et al.
ANN INTERN MED 1990;113:39-52.
ABSTRACT

Late-Onset Neurofibromas Developed in a Patient With Psoriasis Vulgaris During PUVA Treatment
Nishimura and Hori
Arch Dermatol 1990;126:541-542.
ABSTRACT

Elevated Plasma Histamine Levels in Systemic Sclerosis (Scleroderma)
Falanga et al.
Arch Dermatol 1990;126:336-338.
ABSTRACT

Paroxysmal Facial Itch: A Presenting Sign of Childhood Brainstem Glioma
Summers and MacDonald
J Child Neurol 1988;3:189-192.
ABSTRACT

Ketotifen and Neurofibromatosis
Krause
Arch Dermatol 1988;124:651-652.
ABSTRACT

Ketotifen and Neurofibromatosis-Reply
Riccardi and Huston
Arch Dermatol 1988;124:652-652.
ABSTRACT

Chemotherapy of Bilateral Acoustic Neuromas
LEHRER
Arch Otolaryngol Head Neck Surg 1988;114:465-465.
ABSTRACT

New Hope for Neurofibromatosis? The Mast Cell Connection
Claman
JAMA 1987;258:823-823.
ABSTRACT

| | |